Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
adhesive, affiliate, amid, antagonist, Arabi, Arabia, Aspirin, Astra, attainment, Avenue, begun, benchmark, bloodstream, Broadwest, chemotherapy, CINV, commence, compounded, comprised, consecutive, contracted, delete, division, East, Exacerbated, exciting, Excluding, flu, force, goodwill, granisetron, healthy, hundred, inside, issuance, Jordan, Kirin, Kyowa, layer, licensee, LLC, margin, medicine, Middle, nausea, night, notified, occupancy, oncology, patch, pending, permanent, plant, point, preliminary, Premise, receptor, region, rentable, resupply, Rican, Sancuso, Saudi, shipped, slight, slowly, strength, surgery, Tabuk, temporary, therapeutic, thin, threshold, TPr, transdermal, vomiting
Removed:
account, administered, chemical, conform, deadly, deferred, degenerative, domestic, dosing, enter, entity, establishing, expansion, experienced, extended, failure, forgivable, Foxland, government, headquartered, IAS, improved, inception, informed, insurance, kidney, largest, listing, monitoring, nasdaq, offering, participate, partnered, penetrated, Perrigo, pilot, positive, practicable, preclinical, public, rare, record, revised, revision, safely, satisfaction, Solution, statement, summary, surrender, suspended, website
Filing tables
Filing exhibits
Related press release
Associated CPIX transcripts
CPIX similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE AND
CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 of Cumberland Pharmaceuticals Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, A.J. Kazimi, Chief Executive Officer and John Hamm, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that:
1 | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2 | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ A. J. Kazimi | ||
A.J. Kazimi | ||
Chief Executive Officer | ||
May 13, 2022 | ||
/s/ John Hamm | ||
John Hamm | ||
Chief Financial Officer | ||
May 13, 2022 |